Literature DB >> 18729075

Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions.

F Haller1, C Löbke, M Ruschhaupt, H-J Schulten, S Schwager, B Gunawan, T Armbrust, C Langer, G Ramadori, H Sültmann, A Poustka, U Korf, L Füzesi.   

Abstract

Gastrointestinal stromal tumours (GISTs) with deletions in KIT exon 11 are characterized by higher proliferation rates and shorter disease-free survival times, compared to GISTs with KIT exon 11 point mutations. Up-regulation of cyclin D is a crucial event for entry into the G1 phase of the cell cycle, and links mitogenic signalling to cell proliferation. Signalling from activated KIT to cyclin D is directed through the RAS/RAF/ERK, PI3K/AKT/mTOR/EIF4E, and JAK/STATs cascades. ERK and STATs initiate mRNA transcription of cyclin D, whereas EIF4E activation leads to increased translation efficiency and reduced degradation of cyclin D protein. The aim of the current study was to analyse the mRNA and protein expression as well as protein phosphorylation of central hubs of these signalling cascades in primary GISTs, to evaluate whether tumours with KIT exon 11 deletions and point mutations differently utilize these pathways. GISTs with KIT exon 11 deletions had significantly higher mitotic counts, higher proliferation rates, and shorter disease-free survival times. In line with this, they had significantly higher expression of cyclin D on the mRNA and protein level. Furthermore, there was a significantly higher amount of phosphorylated ERK1/2, and a higher protein amount of STAT3, mTOR, and EIF4E. PI3K and phosphorylated AKT were also up-regulated, but this was not significant. Ultimately, GISTs with KIT exon 11 deletions had significantly higher phosphorylation of the central negative cell-cycle regulator RB. Phosphorylation of RB is accomplished by activated cyclin D/CDK4/6 complex, and marks a central event in the release of the cell cycle. Altogether, these observations suggest increased KIT signalling with up-regulation of cyclin D as the basis for the unfavourable clinical course in GISTs with KIT exon 11 deletions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729075     DOI: 10.1002/path.2402

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  [Multilayer analysis of signal transduction and cell cycle control in GIST. Identifying new interaction partners with differential regulation].

Authors:  F Haller; D J Zhang; C Löbke; A von Heydebreck; U Korf; L Füzesi; O Sahin
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  [Molecular biological evaluation of prognostic parameters in GIST. Development of an integrative model of tumor progression].

Authors:  F Haller
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.

Authors:  Eirini Pectasides; Ann-Marie Egloff; Clarence Sasaki; Panteleimon Kountourakis; Barbara Burtness; George Fountzilas; Urania Dafni; Thomas Zaramboukas; Theodoros Rampias; David Rimm; Jennifer Grandis; Amanda Psyrri
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification.

Authors:  Jan C Brase; Heiko Mannsperger; Holger Fröhlich; Stephan Gade; Christian Schmidt; Stefan Wiemann; Tim Beissbarth; Thorsten Schlomm; Holger Sültmann; Ulrike Korf
Journal:  Proteome Sci       Date:  2010-06-22       Impact factor: 2.480

5.  Genomic Grade Index predicts postoperative clinical outcome of GIST.

Authors:  F Bertucci; P Finetti; J Ostrowski; W K Kim; H Kim; M A Pantaleo; A Astolfi; M Polkowski; D Birnbaum
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

6.  Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.

Authors:  Michaela Angelika Ihle; Sebastian Huss; Wiebke Jeske; Wolfgang Hartmann; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Reinhard Büttner; Harri Sihto; Kirsten Sundby Hall; Mikael Eriksson; Peter Reichardt; Heikki Joensuu; Eva Wardelmann
Journal:  PLoS One       Date:  2018-02-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.